Jenő P. Marton - Concepedia

Author

Jenő P. Marton

Pfizer (United States)

Also Known As

Jeno Marton, Jeno P Marton, Jeno P. Marton, Jenõ Marton, Jenö Marton, Jenő P Marton, Jenő P. Marton

Publications

953

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Lovelace Clinic Foundation Research National Jewish Health University of Colorado Denver Morehouse School of Medicine

About

Jenő P. Marton is an author at Pfizer (United States) specializing in public health, medicine, and health services research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Public Health	8	8	331
2	Medicine	7	7	213
3	Epidemiology	2	2	55
4	Endocrinology	1	1	28
5	Geriatrics	1	1	23

Jenő P. Marton

Publications

759

Citations

H-Index

Page 1

	Year	Citations
The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population Joseph Menzin, Luke Boulanger, Jenő P. Marton, Respiratory Medicine Health PolicyHealth EconomicsU.s. Medicare PopulationEconomic BurdenHealth Care Cost	2008	117
Undertreatment of COPD: a retrospective analysis of US managed care and Medicare patients Michael P. Dutro, Make, Paulose-Ram, International Journal of COPD	2012	101
Direct Costs of COPD in the U.S.: An Analysis of Medical Expenditure Panel Survey (MEPS) Data Jeffrey D. Miller, Talia Foster, Luke Boulanger, COPD Journal of Chronic Obstructive Pulmonary Disease	2005	88
Identifying and characterizing COPD patients in US managed care. A retrospective, cross-sectional analysis of administrative claims data Douglas W. Mapel, Michael P. Dutro, Jenő P. Marton, BMC Health Services Research	2011	87
The Cost-Effectiveness of an Extended Course (12 + 12 Weeks) of Varenicline Compared with Other Available Smoking Cessation Strategies in the United States: An Extension and Update to the BENESCO Model C Knight, Paul Howard, Christine L. Baker, Value in Health Tobacco CessationTobacco ControlPreventive MedicineHealth PolicyHealth Economics	2009	59
An Algorithm for the Identification of Undiagnosed COPD Cases Using Administrative Claims Data Douglas W. Mapel, Floyd J. Frost, Judith S. Hurley, Journal of Managed Care Pharmacy	2006	38
Prevalence of renal and hepatobiliary disease, laboratory abnormalities, and potentially toxic medication exposures among persons with COPD Douglas W. Mapel, Jenő P. Marton International Journal of COPD	2013	36
Lost productivity due to premature mortality in developed and emerging countries: an application to smoking cessation Joseph Menzin, Jenő P. Marton, J Menzin, BMC Medical Research Methodology	2012	33
A New Method for Examining the Cost Savings of Reducing COPD Exacerbations Douglas W. Mapel, Michael Schum, Eva Lydick, PharmacoEconomics Cost SavingsEpidemiologyHealth PolicyHealth EconomicsAdvanced Lung Disease	2010	32
(D-Met<sup>2</sup>, Pro<sup>5</sup>)-Enkephalinamide-Induced Blockade of Ovulation and its Reversal by Naloxone in the Rat Katalin Köves, Jenő P. Marton, Judith Molnár, Neuroendocrinology PharmacotherapyFemale Reproductive FunctionExperimental PharmacologyOvarian AgingReproductive Endocrinology	1981	28

Page 1